Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss of $1.13/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
March 8, 2023 7:00 AM EST- Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) -
- First patient enrolled in THRIVE Phase 3 trial in patients with active TED, with results expected in mid-2024 -
- Initial results from the proof-of-concept study of VRDN-001 in patients with chronic TED are expected in the second quarter of 2023 -
- Selection of lead subcutaneous program in TED planned for year-end 2023 -
WALTHAM, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:... More
